Big news for peptides! In July, the FDA will meet to evaluate the most commonly used peptides for FDA authorized compounding. BREAKING: The FDA just reversed their 2023 peptide ban. 12 peptides pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu 5. MOTS C 6. The FDA's Ban of Therapeutic Peptides: A Threat to Health Freedom Slim 'n Sleek FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies FDA Peptide Regulation and HHS Policy Holt Law